Abivax SA American Depositary Shares

About Abivax SA American Depositary Shares

Abivax SA (ABVX) is a France-based clinical-stage biotechnology company pioneering innovative therapeutics for chronic inflammatory diseases. The company specializes in developing drugs that leverage the body's natural regulatory mechanisms to stabilize immune responses in patients suffering from inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease. Abivax's lead candidate, obefazimod, is currently in Phase 3 clinical trials for treating adults with moderately to severely active ulcerative colitis. With a focused R&D strategy centered on gastrointestinal inflammation, Abivax addresses significant unmet medical needs in the IBD market. The company's immunomodulatory approach represents a promising alternative to conventional treatment options, positioning ABVX as a compelling investment opportunity in the growing biotechnology sector for investors seeking exposure to innovative inflammatory disease therapies.